Condition: DLBCL - Diffuse Large B Cell Lymphoma · CAR T Cell Therapy · Sponsor: Miltenyi Biomedicine GmbH
DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.
This description comes directly from the study's public registry record.
Clinical Trial Manager · +4922048306820 · clinicaltrials.gov@miltenyi.com
Always discuss trial participation with your own doctor first.
| National Cancer Center Hospital | Tokyo, Japan | Recruiting |
| Toranomon Hospital | Tokyo, Japan | Not Yet Recruiting |
| Juntendo University Hospital | Tokyo, Japan | Not Yet Recruiting |
| Tokyo Metropolitan Komagome Hospital | Tokyo, Japan | Recruiting |
| Keio University Hospital | Tokyo, Japan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07288879